Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Date:10/26/2010

d to treatment with Zerenex during the safety assessment will be randomized to continue treatment with either Zerenex or placebo for a 4-week period.

About Special Protocol Assessments

The Special Protocol Assessment (SPA) process is a procedure by which the FDA provides official evaluation and written guidance on the design and size of proposed protocols that are intended to form the basis for a new drug application.

Final marketing approval depends on the results of efficacy, the adverse event profile and an evaluation of the benefit/risk of treatment demonstrated in the Phase 3 clinical program. The SPA agreement may only be changed through a written agreement between the sponsor and the FDA, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety. For more information on Special Protocol Assessment, please visit: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf.

About Hyperphosphatemia

In the United States, according to data from the U.S. Renal Data System, there are approximately 485,000 patients with end-stage renal disease, or ESRD, and the number of ESRD patients is projected to rise 60% to approximately 785,000 by 2020. The majority of ESRD patients, close to 400,000, require dialysis. Phosphate retention and the resulting hyperphosphatemia in patients with ESRD on dialysis are usually associated with secondary hyperparathyroidism (and its related cardiovascular complications), renal osteodystrophy and soft tissue mineralization.  ESRD patients usually require treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. The need for alternative phosphate-binding agents has long been recognized, especially given the increasing prevalence of ESRD as well as shortcomings with
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
3. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
4. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
7. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) will ... on Wednesday, May 6, 2015, following the close of the ... conference call and live webcast on the same day at ... discuss the financial results.  To access the ... the "Investors" link.  Please log onto the webcast prior to ...
(Date:4/16/2015)... Kenneth C. Frazier , chairman and chief executive officer ... the Board of the Pharmaceutical Research and Manufacturers of America ... John J. Castellani announced that he will be retiring ... to PhRMA Board Frazier formerly held the position ... and CEO of Pfizer, Inc. Also elected were George ...
(Date:4/16/2015)... YORK , April 16, 2015 An ... additional way to generate trimers from the major HIV ... could benefit future clinical development of HIV vaccine candidates ... the critical target on the surface of HIV for ... an important platform for AIDS vaccine discovery, says ...
Breaking Medicine Technology:Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5New Method Holds Promise for HIV Vaccine Development 2
... Corporation (Nasdaq: GNBT, www.generex.com ), the leader in ... of the mouth, today announced that it has been ... Canadian Intellectual Property Office granted Canadian Patent No. 2,401,942, ... Application". This new patent increases the number ...
... International Corporation (Nasdaq: PRXL ) announced today it ... Conference in New York.  James Winschel, Senior Vice President and ... at 11:45 a.m. ET on Tuesday, October 5, 2010. ... through the "Investors" section of PAREXEL,s website at ...
Cached Medicine Technology:Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 2Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 3PAREXEL International to Present at William Blair Emerging Growth Stock Conference 2
(Date:4/18/2015)... 18, 2015 In the past few ... of changes. , "We had to run maintenance on ... changes," said Jennifer Ramirez, the PR Director. "It disrupted ... say that we are back on track after having ... process of changing phone systems which has not allowed ...
(Date:4/18/2015)... 2015 Aureus Medical Group (web: ... physical therapy jobs, has announced that it will ... Physical Therapy Association Annual Conference to be held ... Greenville, SC. , The SCAPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:4/18/2015)... French physician and gastronome Anthelme Brillat-Savarin ... he uttered, “Tell me what you eat, and I ... cope with stress or sadness has often been attributed ... otherwise. Data collected from their Emotional Eating Test ... eating, but for different reasons. , Collecting data from ...
(Date:4/17/2015)... April 18, 2015 Rosetta Radiology is ... rounding out their list of diagnostic imaging services. This ... patients on the Upper East Side of Manhattan. , ... full capacity. The addition of PET-CT, combined with Rosetta’s ... the ability to work with patients through several stages ...
(Date:4/17/2015)... Alcohol and Violence , The National ... drinking and driving has been the focus of much ... the link between alcohol and crime received less public ... and sexual assault, and their relationship to alcohol have ... million adults in America were drinking alcohol at the ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3
... Company to Also Present Clinical Data at, ... Upcoming Scientific Meeting ... DDSS ) today announced the publication of Extended Release ... the May 2009 issue of the journal Psychiatry (Edgemont) (Volume 6, ...
... German . , When cells cannot carry out ... is disease. Nanobiotechnology researchers are looking for ways to allow ... absent from the cell. This requires transport systems that can ... controlled fashion at the right moment. The transporter must be ...
... May 19 The Pharmaceutical Research and Manufacturers of ... in the research pipeline for diabetes. The report shows ... a record 183 new diabetes medicines. The medicines listed ... trials or are awaiting approval by the U.S. Food ...
... Lilly with Medtronic delivery and glucose sensing leadership INDIANAPOLIS ... recognized names in diabetes management -Eli Lilly and Company ... MDT ) - today announced a strategic ... people with diabetes manage their blood sugar using insulin ...
... Veterinary Care Digital Imaging and Data Management Providers ... Eklin Medical Systems, a leading provider of ... Communications Systems) and practice management software (VIA(R)) for ... Thorn as the company,s West Coast ultrasound representative. ...
... improve our understanding of conditions such as epilepsy and ... University have discovered. , Research by a team ... has discovered that a person,s brain produces a unique ... looks at a visual pattern. , Importantly, the ...
Cached Medicine News:Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 2Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 3Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 4Health News:Capsules encapsulated 2Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 2Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 3Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 4Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 2Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 3Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 4Health News:Eklin Medical Systems Appoints Juan Thorn as West Coast Ultrasound Sales Representative 2Health News:'Singing brains' offers epilepsy and schizophrenia clues 2
... Meet All Nearpoint Testing Needs, ... Horizontal and Vertical Phoria, Binocular ... Visual Acuity Horizontal Fixation Disparity, ... Cylinder, Random Dot Stereopsis Monocular ...
Pediatric: Tumbling "E" Acuity, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Adult: Letter Acuity, Number Acuity, and Tumbling E Tests....
... is a serine protease that is,found only ... of the,acini and ducts. Normal PSA concentration ... Reports have suggested that elevated,level of whole ... useful tumor,markers in diagnosis of prostate cancers. ...
Medicine Products: